Program Expansion Supplement to Cooperative Agreement on Immunization with the World Health Organization (WHO)

Funding Opportunity ID: 286010 Opportunity Number: CDC-RFA-GH13-13010201SUPP16 Opportunity Title: Program Expansion Supplement to Cooperative Agreement on Immunization with the World Health Organization (WHO)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.185Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification)Additional Information on Eligibility: The eligible applicant for this funding opportunity is the World Health Organization (WHO). No other applications are solicited.Agency Code: HHS-CDC-CGHAgency Name: Department of Health and Human ServicesCenters for Disease Control - CGHPosted Date: Jul 12, 2016Close Date: Sep 07, 2016 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date.Last Updated Date: Jul 12, 2016Award Ceiling: $0Award Floor: $0Estimated Total Program Funding: $30,000,000Expected Number of Awards: 1Description: TBDVersion: Synopsis 1
Source: Grants.gov - Category: Research Tags: Health Source Type: funding

Related Links:

Called Winship at Midtown, the nearly $500 million building will consolidate cancer services and improve a patient's experience.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Abstract Human papillomaviruses (HPV) are small, double-stranded DNA viruses that cause cervical cancer, the second most lethal cancer among women in the world. Currently, two vaccines are on the market for preventing HPV-caused cervical cancers and warts. Both are virus-like particle (VLP)-based vaccines. However, these vaccines have limitations; they are costly, have an invasive route of administration, require trained personnel to administer, need cold chain storage to preserve them, and most of all, they are preventive vaccines that do not have curative effects. Therefore, it is necessary to develop therapeuti...
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Tags: J Pharm Pharm Sci Source Type: research
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Article Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Article Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Perspective Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Trends and Innovations Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Snapshot Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Best of the Rest Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Quiz Source Type: news
No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: Bone and Joint in Brief Source Type: news
More News: Department of Health | Funding | Grants | Health | International Medicine & Public Health | Research | WHO